Mitochondrial dynamics: Biology and therapy in lung cancer

Expert Opinion on Investigational Drugs

Volumn 23, Issue 5, 2014, Pages 675-692

  Lennon, Frances E ^a   Salgia, Ravi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

DRP1; Fission; Fusion; Lung cancer; MFN2; Mitochondria; OPA1; Warburg effect

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CALCINEURIN; CARBOPLATIN; CRIZOTINIB; CYCLIN B1; DYNAMIN RELATED PROTEIN 1; DYNEIN ADENOSINE TRIPHOSPHATASE; ERLOTINIB; FOCAL ADHESION KINASE; GEFITINIB; GUANOSINE TRIPHOSPHATASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; K RAS PROTEIN; KINESIN; METFORMIN; MITOCHONDRIAL DNA; MITOCHONDRIAL FISSION PROTEIN; MITOCHONDRIAL PROTEIN; MITOFUSIN 1; MITOFUSIN 2; OPTIC ATROPHY 1; PACLITAXEL; PAXILLIN; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN BAK; PROTEIN BAX; PYRUVATE DEHYDROGENASE KINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VORINOSTAT; ZOLINA; ANTINEOPLASTIC AGENT;

APOPTOSIS; BIOGENESIS; BRAIN CANCER; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL INVASION; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINESIS; ENDOPLASMIC RETICULUM; G2 PHASE CELL CYCLE CHECKPOINT; GLYCOLYSIS; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; METABOLIC DISORDER; MITOCHONDRIAL DNA REPLICATION; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL FISSION; MITOCHONDRIAL FUSION; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOPHAGY; MITOSIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PARANEOPLASTIC SYNDROME; PROTEIN EXPRESSION; REVIEW; SUMOYLATION; ANIMAL; DRUG EFFECTS; LUNG NEOPLASMS; METABOLISM; MITOCHONDRION; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LUNG NEOPLASMS; MITOCHONDRIA; MITOCHONDRIAL DYNAMICS;

EID: 84898456888     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.899350     Document Type: Review

References (122)

1. Cancer statistics surveillance epidemiology and end results. 2013. Available from: Http://seer.cancer.gov/statfacts/html/lungb.html
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29
3. de Groot P, Munden RF. Lung cancer epidemiology, risk factors, and prevention. Radiol Clin North Am 2012;50(5):863-76
4. Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci Transl Med 2013;5(209):209ra153
5. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6(2):244-85
6. Hammerschmidt S, Wirtz H. Lung cancer: Current diagnosis and treatment. Dtsch Arztebl Int 2009;106(49):809-18; quiz 819-820
7. Reungwetwattana T, Weroha SJ, Molina Jr. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (nsclc). Clin Lung Cancer 2012;13(4):252-66
8. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 2010;7(7):401-14
9. Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med 2012;366(6):489-91
10. Frey TG, Mannella CA. The internal structure of mitochondria. Trends Biochem Sci 2000;25(7):319-24
11. Mathews CK, van Holde KE, Appling DR, et al. Biochemistry 2012
12. Warburg O. On the origin of cancer cells. Science 1956;123(3191):309-14
13. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927;8(6):519-30
14. Seyfried TN, Shelton LM. Cancer as a metabolic disease. Nutr Metab 2010;7:7
15. Novello S, Giaj Levra M, Vavala T. Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: A review of existing evidence. Crit Rev Oncol Hematol 2012;83(2):208-15
16. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144(5):646-74
17. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009;324(5930):1029-33
18. Barbosa IA, Machado NG, Skildum AJ, et al. Mitochondrial remodeling in cancer metabolism and survival: Potential for new therapies. Biochim Biophys Acta 2012;1826(1):238-54
19. Chaneton B, Gottlieb E. Rocking cell metabolism: Revised functions of the key glycolytic regulator pkm2 in cancer. Trends Biochem Sci 2012;37(8):309-16
20. Luo W, Semenza GL. Emerging roles of pkm2 in cell metabolism and cancer progression. Trends Endocrinol Metab 2012;23(11):560-6
21. Yoshida S, Tsutsumi S, Muhlebach G, et al. Molecular chaperone trap1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis. Proc Natl Acad Sci USA 2013;110(17):E1604-12
22. Takamura H, Koyama Y, Matsuzaki S, et al. Trap1 controls mitochondrial fusion/fission balance through drp1 and mff expression. PLoS ONE 2012;7(12):e51912
23. Zhang L, Karsten P, Hamm S, et al. Trap1 rescues pink1 loss-of-function phenotypes. Hum Mol Genet 2013;22(14):2829-41
24. Lewis MR, Lewis WH. Mitochondria (and other cytoplasmic structures) in tissue cultures. Am J Anat 1915;17(3):339-401
25. Biesele JJ, Tobioka M. Mitochondria in living cells: An analysis of movements. J Biophys Biochem Cytol 1956;2(4 Suppl):319-24
26. Rossignol R, Gilkerson R, Aggeler R, et al. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res 2004;64(3):985-93
27. Sukhorukov VM, Dikov D, Reichert AS, et al. Emergence of the mitochondrial reticulum from fission and fusion dynamics. PLoS Comput Biol 2012;8(10):e1002745
28. D'Anselmi F, Valerio M, Cucina A, et al. Metabolism and cell shape in cancer: A fractal analysis. Int J Biochem Cell Biol 2011;43(7):1052-8
29. Hardie DG. Amp-Activated protein kinase: An energy sensor that regulates all aspects of cell function. Genes Dev 2011;25(18):1895-908
30. Westermann B. Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol 2010;11(12):872-84
31. Westermann B. Bioenergetic role of mitochondrial fusion and fission. Biochim Biophys Acta 2012;1817(10):1833-8
32. Kubli DA, Gustafsson AB. Mitochondria and mitophagy: The yin and yang of cell death control. Circ Res 2012;111(9):1208-21
33. Martinez-Diez M, Santamaria G, Ortega AD, et al. Biogenesis and dynamics of mitochondria during the cell cycle: Significance of 3'utrs. PloS One 2006;1:e107
34. Kashatus DF, Lim KH, Brady DC, et al. Rala and ralbp1 regulate mitochondrial fission at mitosis. Nat Cell Biol 2011;13(9):1108-15
35. Chan DC. Fusion and fission: Interlinked processes critical for mitochondrial health. Annu Rev Genet 2012;46:265-87
36. Rambold AS, Kostelecky B, Elia N, et al. Tubular network formation protects mitochondria from autophagosomal degradation during nutrient starvation. Proc Natl Acad Sci USA 2011;108(25):10190-5
37. Karbowski M. Mitochondria on guard: Role of mitochondrial fusion and fission in the regulation of apoptosis. Adv Exp Med Biol 2010;687:131-42
38. Fang HY, Chen CY, Chiou SH, et al. Overexpression of optic atrophy 1 protein increases cisplatin resistance via inactivation of caspase-dependent apoptosis in lung adenocarcinoma cells. Hum Pathol 2012;43(1):105-14
39. Taguchi N, Ishihara N, Jofuku A, et al. Mitotic phosphorylation of dynaminrelated gtpase drp1 participates in mitochondrial fission. J Biol Chem 2007;282(15):11521-9
40. Chang CR, Blackstone C. Dynamic regulation of mitochondrial fission through modification of the dynaminrelated protein drp1. Ann N Y Acad Sci 2010;1201:34-9
41. Chou CH, Lin CC, Yang MC, et al. Gsk3beta-mediated drp1 phosphorylation induced elongated mitochondrial morphology against oxidative stress. PLoS One 2012;7(11):e49112
42. Chiang YY, Chen SL, Hsiao YT, et al. Nuclear expression of dynamin-related protein 1 in lung adenocarcinomas. Mod Pathol 2009;22(9):1139-50
43. Kawada I, Hasina R, Lennon FE, et al. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: Relevance to lung cancer. Cancer Biol Ther 2013;14(7):679-91
44. Loson OC, Song Z, Chen H, et al. FIS1, mff, mid49, and mid51 mediate drp1 recruitment in mitochondrial fission. Mol Biol Cell 2013;24(5):659-67
45. Otera H, Wang C, Cleland MM, et al. Mff is an essential factor for mitochondrial recruitment of drp1 during mitochondrial fission in mammalian cells. J Cell Biol 2010;191(6):1141-58
46. Lee S, Jeong SY, Lim WC, et al. Mitochondrial fission and fusion mediators, hfis1 and opa1, modulate cellular senescence. J Biol Chem 2007;282(31):22977-83
47. Lee S, Park YY, Kim SH, et al. Human mitochondrial fis1 links to cell cycle regulators at g2/m transition. Cell Mol Life Sci 2014;71(4):711-25
48. Escobar-Henriques M, Anton F. Mechanistic perspective of mitochondrial fusion: Tubulation vs Fragmentation. Biochim Biophys Acta 2013;1833(1):162-75
49. Chen H, Chomyn A, Chan DC. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J Biol Chem 2005;280(28):26185-92
50. Rowland AA, Voeltz GK. Endoplasmic reticulum-mitochondria contacts: Function of the junction. Nat Rev Mol Cell Biol 2012;13(10):607-25
51. Feely SM, Laura M, Siskind CE, et al. Mfn2 mutations cause severe phenotypes in most patients with cmt2a. Neurology 2011;76(20):1690-6
52. Song Z, Chen H, Fiket M, et al. Opa1 processing controls mitochondrial fusion and is regulated by mrna splicing, membrane potential, and yme1l. J Cell Biol 2007;178(5):749-55
53. Olichon A, Baricault L, Gas N, et al. Loss of opa1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J Biol Chem 2003;278(10):7743-6
54. Lu Y, Rolland SG, Conradt B. A molecular switch that governs mitochondrial fusion and fission mediated by the bcl2-like protein ced-9 of caenorhabditis elegans. Proc Natl Acad Sci USA 2011;108(41):E813-22
55. Karbowski M, Norris KL, Cleland MM, et al. Role of bax and bak in mitochondrial morphogenesis. Nature 2006;443(7112):658-62
56. Cleland MM, Norris KL, Karbowski M, et al. Bcl-2 family interaction with the mitochondrial morphogenesis machinery. Cell Death Differ 2011;18(2):235-47
57. Hoppins S, Edlich F, Cleland MM, et al. The soluble form of bax regulates mitochondrial fusion via mfn2 homotypic complexes. Mol Cell 2011;41(2):150-60
58. Waxman AB, Kolliputi N. Il-6 protects against hyperoxia-induced mitochondrial damage via bcl-2-induced bak interactions with mitofusins. Am J Respir Cell Mol Biol 2009;41(4):385-96
59. Wasiak S, Zunino R, McBride HM. Bax/bak promote sumoylation of drp1 and its stable association with mitochondria during apoptotic cell death. J Cell Biol 2007;177(3):439-50
60. Thomas KJ, Jacobson MR. Defects in mitochondrial fission protein dynamin-related protein 1 are linked to apoptotic resistance and autophagy in a lung cancer model. PLoS One 2012;7(9):e45319
61. Rehman J, Zhang HJ, Toth PT, et al. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J 2012;26(5):2175-86
62. Archer SL. Mitochondrial dynamics-mitochondrial fission and fusion in human diseases. N Engl J Med 2013;369(23):2236-51
63. Lackner LL. Determining the shape and cellular distribution of mitochondria: The integration of multiple activities. Curr Opin Cell Biol 2013;25(4):471-6
64. Ma J, Zheng J, Li Y, et al. Cxcl12 induces lung cancer cell migration by polarized mtdna redistribution. Hum Cell 2014;27(1):22-8
65. Reis K, Fransson A, Aspenstrom P. The miro gtpases: At the heart of the mitochondrial transport machinery. FEBS Lett 2009;583(9):1391-8
66. Desai SP, Bhatia SN, Toner M, et al. Mitochondrial localization and the persistent migration of epithelial cancer cells. Biophys J 2013;104(9):2077-88
67. Zhao J, Zhang J, Yu M, et al. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene 2013;32(40):4814-24
68. Golubovskaya VM. Focal adhesion kinase as a cancer therapy target. Anticancer Agents Med Chem 2010;10(10):735-41
69. Tornatore TF, Dalla Costa AP, Clemente CF, et al. A role for focal adhesion kinase in cardiac mitochondrial biogenesis induced by mechanical stress. Am J Physiol Heart Circ Physiol 2011;300(3):H902-12
70. Crane JD, Ogborn DI, Cupido C, et al. Massage therapy attenuates inflammatory signaling after exercise-induced muscle damage. Sci Transl Med 2012;4(119):119ra113
71. Caino MC, Chae YC, Vaira V, et al. Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J Clin Invest 2013;123(7):2907-20
72. Lee YJ, Jeong SY, Karbowski M, et al. Roles of the mammalian mitochondrial fission and fusion mediators fis1, drp1, and opa1 in apoptosis. Mol Biol Cell 2004;15(11):5001-11
73. Scorrano L. Multiple functions of mitochondria-shaping proteins. Novartis Found Symp 2007;287:47-55; discussion 55-49
74. Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol 2012;6(6):579-89
75. Jakopovic M, Thomas A, Balasubramaniam S, et al. Targeting the epigenome in lung cancer: Expanding approaches to epigenetic therapy. Front Oncol 2013;3:261
76. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27(32):5459-68
77. Lee JS, Yoon YG, Yoo SH, et al. Histone deacetylase inhibitors induce mitochondrial elongation. J Cell Physiol 2012;227(7):2856-69
78. Amoedo ND, Rodrigues MF, Pezzuto P, et al. Energy metabolism in h460 lung cancer cells: Effects of histone deacetylase inhibitors. PLoS One 2011;6(7):e22264
79. Lackner LL, Nunnari J. Small molecule inhibitors of mitochondrial division: Tools that translate basic biological research into medicine. Chem Biol 2010;17(6):578-83
80. Sutendra G, Michelakis ED. Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Front Oncol 2013;3:38
81. Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-k+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;11(1):37-51
82. Robey IF, Martin NK. Bicarbonate and dichloroacetate: Evaluating ph altering therapies in a mouse model for metastatic breast cancer. BMC Cancer 2011;11:235
83. Michelakis ED, Sutendra G, Dromparis P, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2010;2(31):31ra34
84. Picard M, Shirihai OS, Gentil BJ, et al. Mitochondrial morphology transitions and functions: Implications for retrograde signaling? Am J Physiol Regul Integr Comp Physiol 2013;304(6):R393-406
85. Vander Heiden MG, Christofk HR, Schuman E, et al. Identification of small molecule inhibitors of pyruvate kinase m2. Biochem Pharmacol 2010;79(8):1118-24
86. Porporato PE, Dhup S, Dadhich RK, et al. Anticancer targets in the glycolytic metabolism of tumors: A comprehensive review. Front Pharmacol 2011;2:49
87. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013;4:e532
88. Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: An overview. Clin Sci (Lond) 2012;122(6):253-70
89. Bhatt MP, Lim YC, Kim YM, et al. C-peptide activates ampkalpha and prevents ros-mediated mitochondrial fission and endothelial apoptosis in diabetes mellitus. Diabetes 2013;62(11):3851-62
90. Javeshghani S, Zakikhani M, Austin S, et al. Carbon source and myc expression influence the antiproliferative actions of metformin. Cancer Res 2012;72(23):6257-67
91. Mazzone PJ, Rai H, Beukemann M, et al. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer 2012;12:410
92. Storozhuk Y, Hopmans SN, Sanli T, et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (nsclc) through atm and ampk. Br J Cancer 2013;108(10):2021-32
93. Morgillo F, Sasso FC, Della Corte CM, et al. Synergistic effects of metformin treatment in combination with gefitinib, a selective egfr tyrosine kinase inhibitor, in lkb1 wild-Type nsclc cell lines. Clin Cancer Res 2013;19(13):3508-19
94. Shokolenko IN, Wilson GL, Alexeyev MF. Persistent damage induces mitochondrial DNA degradation. DNA Repair (Amst) 2013;12(7):488-99
95. Chamberlain GR, Tulumello DV, Kelley SO. Targeted delivery of doxorubicin to mitochondria. ACS Chem Biol 2013;8(7):1389-95
96. Jhaveri K, Taldone T, Modi S, et al. Advances in the clinical development of heat shock protein 90 (hsp90) inhibitors in cancers. Biochim Biophys Acta 2012;1823(3):742-55
97. Kang BH. Trap1 regulation of mitochondrial life or death decision in cancer cells and mitochondria-Targeted trap1 inhibitors. BMB Rep 2012;45(1):1-6
98. Kang BH, Plescia J, Song HY, et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial hsp90. J Clin Invest 2009;119(3):454-64
99. Kang BH, Siegelin MD, Plescia J, et al. Preclinical characterization of mitochondria-Targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res 2010;16(19):4779-88
100. Rosell R, Viteri S, Molina MA, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Curr Opin Oncol 2010;22(2):112-20
101. Alamgeer M, Ganju V, Neil Watkins D. Novel therapeutic targets in non-small cell lung cancer. Curr Opin Pharmacol 2013;13(3):394-401
102. Nelson V, Ziehr J, Agulnik M, et al. Afatinib: Emerging next-generation tyrosine kinase inhibitor for nsclc. OncoTargets Ther 2013;6:135-43
103. Kim SM, Yun MR, Hong YK, et al. Glycolysis inhibition sensitizes non-small cell lung cancer with t790m mutation to irreversible egfr inhibitors via translational suppression of mcl-1 by ampk activation. Mol Cancer Ther 2013;12(10):2145-56
104. Roberts PJ, Stinchcombe TE. Kras mutation: Should we test for it, and does it matter? J Clin Oncol 2013;31(8):1112-21
105. Toyooka S, Mitsudomi T, Soh J, et al. Molecular oncology of lung cancer. Gen Thorac Cardiovasc Surg 2011;59(8):527-37
106. Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for kras-mutant advanced non-small-cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013;14(1):38-47
107. Baines AT, Xu D, Der CJ. Inhibition of ras for cancer treatment: The search continues. Future Med Chem 2011;3(14):1787-808
108. Weinberg F, Hamanaka R, Wheaton WW, et al. Mitochondrial metabolism and ros generation are essential for kras-mediated tumorigenicity. Proc Natl Acad Sci USA 2010;107(19):8788-93
109. Commisso C, Davidson SM, Soydaner-Azeloglu RG, et al. Macropinocytosis of protein is an amino acid supply route in ras-Transformed cells. Nature 2013;497(7451):633-7
110. De Raedt T, Walton Z, Yecies JL, et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell 2011;20(3):400-13
111. Frank M, Duvezin-Caubet S, Koob S, et al. Mitophagy is triggered by mild oxidative stress in a mitochondrial fission dependent manner. Biochim Biophys Acta 2012;1823(12):2297-310
112. La Madrid AM, Campbell N, Smith S, et al. Targeting alk: A promising strategy for the treatment of non-small cell lung cancer, non-hodgkin's lymphoma, and neuroblastoma. Target Oncol 2012;7(3):199-210
113. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming eml4-Alk fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561-6
114. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131(6):1190-203
115. Ou SH, Bartlett CH, Mino-Kenudson M, et al. Crizotinib for the treatment of alk-rearranged non-small cell lung cancer: A success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012;17(11):1351-75
116. Choi H, Paeng JC, Kim DW, et al. Metabolic and metastatic characteristics of alk-rearranged lung adenocarcinoma on fdg pet/ct. Lung Cancer 2013;79(3):242-7
117. Scagliotti GV, Novello S, von Pawel J. The emerging role of met/hgf inhibitors in oncology. Cancer Treat Rev 2013;39(7):793-801
118. Broggini M, Garassino MC, Damia G. Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer. Cancer Manage Res 2013;5:15-20
119. Tsuta K, Kozu Y, Mimae T, et al. C-met/phospho-met protein expression and met gene copy number in non-small cell lung carcinomas. J Thorac Oncol 2012;7(2):331-9
120. Nitsch D, Goncalves JP, Ojeda F, et al. Candidate gene prioritization by network analysis of differential expression using machine learning approaches. BMC Bioinformatics 2010;11:460
121. Jensen LJ, Kuhn M, Stark M, et al. String 8-A global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 2009;37(Database issue):D412-16
122. Sulakhe D, Balasubramanian S, Xie B, et al. Lynx: A database and knowledge extraction engine for integrative medicine. Nucleic Acids Res 2014;42(Database issue):D1007-12